Shares of Sai Life Sciences climbed 3.49% to ₹750.85 on Tuesday following a strong financial performance in Q4 FY25. The stock gained ₹25.30 in early trade as investors responded positively to the company’s solid revenue growth and profit surge.
For the quarter ended March 2025, the company reported a 57.26% year-on-year jump in net profit to ₹88.27 crore, compared to ₹56.13 crore in the same quarter last year. Sales rose 31.94% to ₹579.51 crore from ₹439.21 crore during the corresponding period.
Operationally, PBDT for the quarter stood at ₹156.29 crore, up 46% YoY, while PBT increased by 56% to ₹118.80 crore. However, the operating profit margin (OPM) saw a slight decline to 27.19% from 28.38%.
For the full financial year ended March 2025, net profit more than doubled to ₹170.13 crore, a 105.45% increase over ₹82.81 crore in FY24. Annual sales grew 15.66% to ₹1,694.57 crore compared to ₹1,465.18 crore in the previous year.
At 9:35 AM, Sai Life Sciences shares were trading at ₹750.85 with a market cap of ₹156.76 billion. The day’s range stood between ₹735.60 and ₹770.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
